Gary Hantsbarger

983 total citations
20 papers, 785 citations indexed

About

Gary Hantsbarger is a scholar working on Surgery, Genetics and Ophthalmology. According to data from OpenAlex, Gary Hantsbarger has authored 20 papers receiving a total of 785 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Genetics and 5 papers in Ophthalmology. Recurrent topics in Gary Hantsbarger's work include Inflammatory Bowel Disease (8 papers), Anorectal Disease Treatments and Outcomes (5 papers) and Diverticular Disease and Complications (5 papers). Gary Hantsbarger is often cited by papers focused on Inflammatory Bowel Disease (8 papers), Anorectal Disease Treatments and Outcomes (5 papers) and Diverticular Disease and Complications (5 papers). Gary Hantsbarger collaborates with scholars based in United States, United Kingdom and Switzerland. Gary Hantsbarger's co-authors include Philip J. Rosenfeld, Jeffrey S. Heier, Naveed Shams, Andrew N. Antoszyk, Thomas A. Ciulla, Steven R. Leff, Richard F. Dreyer, Ronald C. Gentile, Peter R. Pavan and Judy P. Sy and has published in prestigious journals such as Circulation, Gastroenterology and Journal of the American College of Cardiology.

In The Last Decade

Gary Hantsbarger

18 papers receiving 743 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Hantsbarger United States	10	416	288	183	174	125	20	785
Christopher M. Frank United States	9	582 1.4×	187 0.6×	155 0.8×	36 0.2×	75 0.6×	11	681
Iris Steinbrugger Austria	11	308 0.7×	181 0.6×	12 0.1×	9 0.1×	57 0.5×	17	396
B. Daicker Switzerland	13	415 1.0×	212 0.7×	36 0.2×	13 0.1×	190 1.5×	89	677
Hidetoshi Kaneoka Japan	13	146 0.4×	22 0.1×	53 0.3×	14 0.1×	172 1.4×	22	478
Mahdy Ranjbar Germany	14	370 0.9×	233 0.8×	18 0.1×	8 0.0×	135 1.1×	73	585
Michael S. Cunnington United Kingdom	11	6 0.0×	129 0.4×	150 0.8×	242 1.4×	262 2.1×	33	643
T. Böker Germany	13	309 0.7×	219 0.8×	78 0.4×	5 0.0×	99 0.8×	28	691
John H. Lillvis United States	11	28 0.1×	28 0.1×	86 0.5×	33 0.2×	75 0.6×	18	334
Jonathan Hinton United Kingdom	7	7 0.0×	61 0.2×	118 0.6×	93 0.5×	134 1.1×	42	393
Maryam Tahvildari United States	13	54 0.1×	150 0.5×	27 0.1×	7 0.0×	56 0.4×	21	403

Countries citing papers authored by Gary Hantsbarger

Since Specialization

Citations

This map shows the geographic impact of Gary Hantsbarger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Hantsbarger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Hantsbarger more than expected).

Fields of papers citing papers by Gary Hantsbarger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Hantsbarger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Hantsbarger. The network helps show where Gary Hantsbarger may publish in the future.

Co-authorship network of co-authors of Gary Hantsbarger

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Hantsbarger. A scholar is included among the top collaborators of Gary Hantsbarger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Hantsbarger. Gary Hantsbarger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karki, Chitra, Gary Hantsbarger, Erika Turkstra, et al.. (2024). Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn’s disease. BMC Gastroenterology. 24(1). 479–479. 1 indexed citations

Karki, Chitra, et al.. (2023). Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases. PharmacoEconomics - Open. 7(5). 811–822.

Karki, Chitra, et al.. (2023). Multi-national observational study to assess quality of life and treatment preferences in patients with Crohn’s perianal fistulas. World Journal of Gastrointestinal Surgery. 15(11). 2537–2552. 6 indexed citations

Zmora, Oded, Daniel C. Baumgart, William A. Faubion, et al.. (2022). P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas. Journal of Crohn s and Colitis. 16(Supplement_1). i536–i537. 9 indexed citations

Panés, Julián, Gerd Bouma, Marc Ferrante, et al.. (2022). INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn’s Disease Treated in the ADMIRE-CD Trial. Inflammatory Bowel Diseases. 28(11). 1737–1745. 35 indexed citations

Karki, Chitra, Gary Hantsbarger, Snježana Miličević, et al.. (2022). P516 Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study. Journal of Crohn s and Colitis. 16(Supplement_1). i472–i473.

Card, Tim, Ryan C. Ungaro, Fatima Bhayat, et al.. (2019). Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post‐marketing data. Alimentary Pharmacology & Therapeutics. 51(1). 149–157. 28 indexed citations

Card, Tim, Ryan C. Ungaro, Fatima Bhayat, et al.. (2019). Su1835 – Vedolizumab Use is Not Associated with Increased Malignancy Incidence: Gemini Long-Term Safety Study Results and Post-Marketing Data. Gastroenterology. 156(6). S–628. 1 indexed citations

Cohen, Russell D., Fatima Bhayat, Gary Hantsbarger, Aimee Blake, & Séverine Vermeire. (2018). DOP005 Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists. Journal of Crohn s and Colitis. 12(supplement_1). S032–S034. 2 indexed citations

10.

Novack, Gary D., Richard A. Lewis, Roger Vogel, et al.. (2013). Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers. Journal of Ocular Pharmacology and Therapeutics. 29(7). 674–680. 25 indexed citations

11.

Martin, Nancy, Richard A. Lewis, Roger Vogel, et al.. (2012). 686 Randomised, double-blind, placebo-controlled study to assess the ocular safety of mirabegron in normotensive IOP research subjects. European Urology Supplements. 11(1). e686–e686a. 4 indexed citations

12.

Rosenfeld, Philip J., Jeffrey S. Heier, Gary Hantsbarger, & Naveed Shams. (2006). Tolerability and Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular Degeneration. Ophthalmology. 113(4). 623–632.e1. 154 indexed citations

13.

Heier, Jeffrey S., Andrew N. Antoszyk, Peter R. Pavan, et al.. (2006). Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology. 113(4). 633–642.e4. 308 indexed citations

14.

Heier, Jeffrey S., et al.. (2005). Long–Term Experience With LucentisTM (Ranibizumab) in Patients With Neovascular Age–Related Macular Degeneration (AMD). 46(13). 1393–1393. 4 indexed citations

15.

Kereiakes, Dean J., Neal S. Kleiman, James J. Ferguson, et al.. (1998). Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban. Circulation. 98(13). 1268–1278. 81 indexed citations

16.

Kereiakes, Dean J., Neal S. Kleiman, James J. Ferguson, et al.. (1997). Sustained Platelet Glycoprotein IIb/IIIa Blockade With Oral Xemilofiban in 170 Patients After Coronary Stent Deployment. Circulation. 96(4). 1117–1121. 56 indexed citations

17.

Kereiakes, Dean J., John Paul Runyon, Neal S. Kleiman, et al.. (1996). Differential Dose-Response to Oral Xemilofiban After Antecedent Intravenous Abciximab. Circulation. 94(5). 906–910. 50 indexed citations

18.

Anders, Robert J., John C. Alexander, Gary Hantsbarger, et al.. (1995). 931-113 Demonstration of Potent Inhibition of Platelet Aggregation with an Orally Active GPllb/IIIA Receptor Antagonist. Journal of the American College of Cardiology. 25(2). 117A–117A. 8 indexed citations

19.

Rainsford, K. D., R H Hunt, Paul Stetsko, et al.. (1992). Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers. Clinical Pharmacology & Therapeutics. 51(4). 415–421. 9 indexed citations

20.

Dysken, Maurice W., T Fakouhi, Stacy Skare, et al.. (1992). Milacemide: Safety assessment in senile dementia of the Alzheimer type. Drug Development Research. 27(1). 67–72. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact